Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylene blue for resuscitated cardiac arrest
ACTRN12625000828426Phase 2Recruiting
- Sponsor
- The Alfred Hospital
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in cardiac arrest (SCA) comparing Methylene blue + standard medical care with Placebo + standard medical care (2 arms). Primary endpoints: Change from baseline in serum neuron specific enolase concentration, Survival with favourable neurological outcome at hospital discharge and 1 more. Started Feb 2026; status: recruiting.
02
Drugs
methylene blue
03
Conditions
cardiac arrest (SCA)
Beyond the preview
Go deeper on ACTRN12625000828426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000828426.